98
Views
33
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Plasma Resistin Levels in Asthmatics as a Marker of Disease State

, M.D., , M.D., , M.D. & , M.D.
Pages 509-513 | Published online: 02 Jul 2009

References

  • http://www.cdc.gov/nchs/fastats/asthma.htm FastStats A to Z: asthma. Available at. Accessed 15 Jan 2006
  • Asthma in America Survey. Executive Summary, http://www.asthmainamerica.com/aaa_index.html Available at. Accessed 15 Jan 2006
  • Asthma in America Survey. Executive Summary, http://www.asthmainamerica.com/slides/slide20.htm Available at. Accessed 15 Jan 2006
  • Leuppi J D, Salome C M, Jenkins C R, Anderson S D, Xuan W, Marks G B, Koskela H, Brannan J D, Freed R, Andersson M, Chan H K, Woolcock A J. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406–412
  • Deykin A, Lazarus S C, Fahy J V, Wechsler M E, Boushey H A, Chinchilli V M, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115: 720–727
  • Bousquet J, Chanez P, Lacoste J Y, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–1039
  • Jatakanon A, Lim S, Barnes P J. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161: 64–72
  • Jatakanon A, Lim S, Kharitonov S A, Chung K F, Barnes P J. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53: 91–95
  • Jeffrey P K, Wardlaw A J, Nelson F C, Collins J V, Kay A B. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140: 1745–1753
  • Saraiva-Romanholo B M, Barnabe V, Carvalho A L, Martins M A, Saldiva P H, Nunes Mdo P. Comparison of three methods for differential cell count in induced sputum. Chest 2003; 124: 1060–1066
  • Vints A M, Oostveen E, Eeckhaut G, Smolders M, De Backer W A. Time-dependent effect of nitrate-rich meals on exhaled nitric oxide in healthy subjects. Chest 2005; 128: 2465–2470
  • McTernan P G, Fisher F M, Valsamakis G, Chetty R, Harte A, McTernan C L, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipoctyes. J Clin Endocrinol Metab 2003; 88: 6098–6106
  • Steppan C M, Brown E J, Wright C M, Baht S, Banerjee R R, Dai Cy, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98: 502–506
  • Hartman H B, Hu X, Tyler K X, Dalal C K, Lazar M A. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277: 19754–19761
  • Lee J H, Chan J L, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848–4856
  • Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561–564
  • Patel L, Buckels A C, Kinghorn I J, Murdock P R, Holbrook J D, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 2003; 300: 472–476
  • Savage D B, Sewter C P, Klenk E S, Segal D G, Vidal-Puig A, Considine R V, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-[gamma] action in humans. Diabetes 2001; 50: 2199–2202
  • Youn B S, Yu K Y, Park H J, Lee N S, Min S S, Youn Y M, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150–156
  • Hirosumi J, Tuncman G, Chang L, Gorgun C Z, Uysal K T, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333–336
  • Holcomb I N, Kabakoff R C, Chan B, Baker T W, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19: 4046–4055
  • Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415–419
  • Lu S C, Scieh W Y, Chen C Y, Hsu S C, Chen H L. Lipopolysaccharide increases resistin gene expression in vivo in vitro. FEBS Lett 2002; 530: 158–162
  • Rajala M W, Lin Y, Ranalletta M. Cell type-specific expression and coregulation of murine molecule-α in adipose tissue. Mol Endocrinol 2002; 16: 1920–1930
  • Silswal N, Singh A K, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham N Z. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092–1101
  • Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z W, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673–1677
  • McTernan P G, McTernan C L, Chetty R, Jenner K, Fisher F M, Lauer M N, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407–2410
  • DeBrosse C W, Zimmermann N, King N E, Pope S M, Fulkerson P C, Mishra A, et al. C2 induction of resistin-like molecule beta (relm-beta) by respiratory allergen, IL-4, IL-13 and stat6 in experimental asthma. J Allergy Clin Immunol 2003; 111: 901
  • Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report 2. National Institutes of Health, Bethesda, MD 1997, NIH publication 97-4051
  • NHLBI/WHO Workshop Report. Global strategy for asthma management and prevention. Global initiative for asthma. National Institutes of Health, Bethesda, MD 1995, NIH publication 95-3659
  • Jousilahti P, Salomaa V, Hakala K, Rasi V, Vahtera E, Palosuo T. The association of sensitive systemic inflammatory markers with bronchial asthma. Ann Allergy Asthma Immunol 2002; 89: 381–385
  • Humbles A A, Lu B, Nilsson C A, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406: 998–1001
  • Krug N, Tschernig T, Erpenbeck V J, Hohlfeld J M, Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164: 1841–1843
  • Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003; 112: 525–530

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.